Acquisition Expands Okogen’s Pipeline from Eyecare to Global Antiviral Platform PLANO, Texas — March 26, 2026 Okogen Inc., a biotechnology company developing antiviral therapeutics, today announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from